{"id":"vizimpro","rwe":[],"_fda":{"id":"cf672c83-c9d9-4107-bcf1-76d4106537cc","set_id":"4ab27d2f-e385-4e9c-b324-fa69c10b855a","openfda":{"upc":["0300691198308","0300692299301","0300690197302"],"unii":["5092U85G58"],"route":["ORAL"],"rxcui":["2058915","2058922","2058924","2058926","2058930","2058932"],"spl_id":["cf672c83-c9d9-4107-bcf1-76d4106537cc"],"brand_name":["Vizimpro"],"spl_set_id":["4ab27d2f-e385-4e9c-b324-fa69c10b855a"],"package_ndc":["0069-0197-30","0069-1198-30","0069-2299-30"],"product_ndc":["0069-0197","0069-1198","0069-2299"],"generic_name":["DACOMITINIB"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["DACOMITINIB"],"manufacturer_name":["Pfizer Laboratories Div Pfizer Inc"],"application_number":["NDA211288"],"is_original_packager":[true]},"version":"8","pregnancy":["8.1 Pregnancy Risk Summary Based on findings from animal studies and its mechanism of action, VIZIMPRO can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1) ] . There are no available data on VIZIMPRO use in pregnant women. In animal reproduction studies, oral administration of dacomitinib to pregnant rats during the period of organogenesis resulted in an increased incidence of post-implantation loss and reduced fetal body weight at doses resulting in exposures near the exposure at the 45 mg human dose (see Data) . The absence of EGFR signaling has been shown to result in embryolethality as well as post-natal death in animals (see Data) . Advise pregnant women of the potential risk to a fetus [see Use in Special Populations (8.3) ] . In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data Daily oral administration of dacomitinib to pregnant rats during the period of organogenesis resulted in an increased incidence of post-implantation loss, maternal toxicity, and reduced fetal body weight at 5 mg/kg/day (approximately 1.2 times the exposure based on area under the curve [AUC] at the 45 mg human dose). Disruption or depletion of EGFR in mouse models has shown EGFR is critically important in reproductive and developmental processes including blastocyst implantation, placental development, and embryo-fetal/post-natal survival and development. Reduction or elimination of embryo-fetal or maternal EGFR signaling in mice can prevent implantation, and can cause embryo-fetal loss during various stages of gestation (through effects on placental development), developmental anomalies, early death in surviving fetuses, and adverse developmental outcomes in multiple organs in embryos/neonates."],"description":["11 DESCRIPTION Dacomitinib is an oral kinase inhibitor with a molecular formula of C 24 H 25 ClFN 5 O 2 ∙ H 2 O and a molecular weight of 487.95 Daltons. The chemical name is: (2 E )- N -{4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}-4-(piperidin-1-yl)but-2-enamide monohydrate and its structural formula is: Dacomitinib is a white to pale yellow powder. VIZIMPRO tablets contain 45, 30, or 15 mg of dacomitinib with the following inactive ingredients in the tablet core; lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, and magnesium stearate. The film coating consists of Opadry II ® Blue 85F30716 containing: Polyvinyl alcohol – partially hydrolyzed, Talc, Titanium dioxide, Macrogol/PEG 3350, and FD&C Blue #2/Indigo Carmine Aluminum Lake. Chemical Structure"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING VIZIMPRO is supplied in strengths and package configurations as described in Table 6 below: Table 6. VIZIMPRO Strengths and Package Configurations VIZIMPRO Tablets Package Configuration Tablet Strength (mg) NDC Tablet Description 30-Count Bottle with a child-resistant closure 15 0069-0197-30 Blue film-coated, immediate release, round biconvex tablet, debossed with \"Pfizer\" on one side and \"DCB15\" on the other side. 30-Count Bottle with a child-resistant closure 30 0069-1198-30 Blue film-coated immediate release, round biconvex tablet, debossed with \"Pfizer\" on one side and \"DCB30\" on the other side. 30-Count Bottle with a child-resistant closure 45 0069-2299-30 Blue film-coated immediate release, round biconvex tablet, debossed with \"Pfizer\" on one side and \"DCB45\" on the other side. Store at 20 °C to 25 °C (68 °F to 77 °F); excursions permitted between 15 °C to 30 °C (59 °F to 86 °F). [see USP Controlled Room Temperature]."],"geriatric_use":["8.5 Geriatric Use Of the total number of patients (N=394) in five clinical studies with EGFR mutation-positive NSCLC who received VIZIMPRO at a dose of 45 mg orally once daily [ARCHER 1050 (N=227), Study A7471009 (N=38), Study A7471011 (N=83), Study A7471028 (N=16), and Study A7471017 (N=30)] 40% were 65 years of age and older. Exploratory analyses across this population suggest a higher incidence of Grade 3 and 4 adverse reactions (67% versus 56%, respectively), more frequent dose interruptions (53% versus 45%, respectively), and more frequent discontinuations (24% versus 10%, respectively) for adverse reactions in patients 65 years or older as compared to those younger than 65 years."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of VIZIMPRO in pediatrics have not been established."],"effective_time":"20251218","clinical_studies":["14 CLINICAL STUDIES The efficacy of VIZIMPRO was demonstrated in a randomized, multicenter, multinational, open-label study (ARCHER 1050; [NCT01774721]). Patients were required to have unresectable, metastatic NSCLC with no prior therapy for metastatic disease or recurrent disease with a minimum of 12 months disease-free after completion of systemic therapy; an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; EGFR exon 19 deletion or exon 21 L858R substitution mutations. EGFR mutation status was prospectively determined by local laboratory or commercially available tests (e.g., therascreen ® EGFR RGQ PCR and cobas ® EGFR Mutation Test). Patients were randomized (1:1) to receive VIZIMPRO 45 mg orally once daily or gefitinib 250 mg orally once daily until disease progression or unacceptable toxicity. Randomization was stratified by region (Japanese versus mainland Chinese versus other East Asian versus non-East Asian), and EGFR mutation status (exon 19 deletions versus exon 21 L858R substitution mutation). The major efficacy outcome measure was progression-free survival (PFS) as determined by blinded Independent Radiologic Central (IRC) review per RECIST v1.1. Additional efficacy outcome measures were overall response rate (ORR), duration of response (DoR), and overall survival (OS). A total of 452 patients were randomized to receive VIZIMPRO (N=227) or gefitinib (N=225). The demographic characteristics were 60% female; median age 62 years (range: 28 to 87), with 40% aged 65 years and older; and 23% White, 77% Asian, and less than 1% Black. Prognostic and tumor characteristics were ECOG performance status 0 (30%) or 1 (70%); 59% with exon 19 deletion and 41% with exon 21 L858R substitution; Stage IIIB (8%) and Stage IV (92%); 64% were never smokers; and 1% received prior adjuvant or neoadjuvant therapy. ARCHER 1050 demonstrated a statistically significant improvement in PFS as determined by the IRC. Results are summarized in Table 5 and Figures 1 and 2. The hierarchical statistical testing order was PFS followed by ORR and then OS. No formal testing of OS was conducted since the formal comparison of ORR was not statistically significant. Table 5. Efficacy Results in ARCHER 1050 VIZIMPRO N=227 Gefitinib N=225 CI=confidence interval; DoR=duration of response; HR=hazard ratio; IRC=Independent Radiologic Central; N/n=total number; PFS=progression-free survival. Progression-Free Survival (per IRC) Number of patients with event, n (%) 136 (59.9%) 179 (79.6%) Median PFS in months (95% CI) 14.7 (11.1, 16.6) 9.2 (9.1, 11.0) HR (95% CI) From stratified Cox Regression. 0.59 (0.47, 0.74) p-value Based on the stratified log-rank test. <0.0001 Overall Response Rate (per IRC) Overall Response Rate % (95% CI) 75% (69, 80) 72% (65, 77) p-value Based on the stratified Cochran-Mantel-Haenszel test. 0.39 Duration of Response in Responders (per IRC) Median DoR in months (95% CI) 14.8 (12.0, 17.4) 8.3 (7.4, 9.2) Figure 1. Kaplan-Meier Curve for PFS per IRC Review in ARCHER 1050 Figure 2. Kaplan-Meier Curve for OS in ARCHER 1050 Figure 1 Figure 2"],"pharmacodynamics":["12.2 Pharmacodynamics Cardiac Electrophysiology The effect of dacomitinib on the QT interval corrected for heart rate (QTc) was evaluated using time-matched electrocardiograms (ECGs) evaluating the change from baseline and corresponding pharmacokinetic data in 32 patients with advanced NSCLC. Dacomitinib had no large effect on QTc (i.e., >20 ms) at maximum dacomitinib concentrations achieved with VIZIMPRO 45 mg orally once daily. Exposure-Response Relationships Higher exposures, across the range of exposures with the recommended dose of 45 mg daily, correlated with an increased probability of Grade ≥3 adverse events, specifically dermatologic toxicities and diarrhea."],"pharmacokinetics":["12.3 Pharmacokinetics The maximum dacomitinib plasma concentration (C max ) and AUC at steady state increased proportionally over the dose range of VIZIMPRO 2 mg to 60 mg orally once daily (0.04 to 1.3 times the recommended dose) across dacomitinib studies in patients with cancer. At a dose of 45 mg orally once daily, the geometric mean [coefficient of variation (CV%)] C max was 108 ng/mL (35%) and the AUC 0–24h was 2213 ng∙h/mL (35%) at steady state in a dose-finding clinical study conducted in patients with solid tumors. Steady state was achieved within 14 days following repeated dosing and the estimated geometric mean (CV%) accumulation ratio was 5.7 (28%) based on AUC. Absorption The mean absolute bioavailability of dacomitinib is 80% after oral administration. The median dacomitinib time to reach maximum concentration (T max ) occurred at approximately 6.0 hours (range 2.0 to 24 hours) after a single oral dose of VIZIMPRO 45 mg in patients with cancer. Effect of Food Administration of VIZIMPRO with a high-fat, high-calorie meal (approximately 800 to 1000 calories with 150, 250, and 500 to 600 calories from protein, carbohydrate and fat, respectively) had no clinically meaningful effect on dacomitinib pharmacokinetics. Distribution The geometric mean (CV%) volume of distribution of dacomitinib (V ss ) was 1889 L (18%). In vitro binding of dacomitinib to human plasma proteins is approximately 98% and is independent of drug concentrations from 250 ng/mL to 1000 ng/mL. Elimination Following a single 45 mg oral dose of VIZIMPRO in patients with cancer, the mean (CV%) plasma half-life of dacomitinib was 70 hours (21%), and the geometric mean (CV%) apparent plasma clearance of dacomitinib was 24.9 L/h (36%). Metabolism Hepatic metabolism is the main route of clearance of dacomitinib, with oxidation and glutathione conjugation as the major pathways. Following oral administration of a single 45 mg dose of [ 14 C] dacomitinib, the most abundant circulating metabolite was O-desmethyl dacomitinib, which had similar in vitro pharmacologic activity as dacomitinib. The steady-state plasma trough concentration of O-desmethyl dacomitinib ranges from 7.4% to 19% of the parent. In vitro studies indicated that cytochrome P450 (CYP) 2D6 was the major isozyme involved in the formation of O-desmethyl dacomitinib, while CYP3A4 contributed to the formation of other minor oxidative metabolites. Excretion Following a single oral 45 mg dose of [ 14 C] radiolabeled dacomitinib, 79% of the radioactivity was recovered in feces (20% as dacomitinib) and 3% in urine (<1% as dacomitinib). Specific Populations Patients with Renal Impairment Based on population pharmacokinetic analyses, mild (60 mL/min ≤CLcr <90 mL/min; N=590) and moderate (30 mL/min ≤CLcr <60 mL/min; N=218) renal impairment did not alter dacomitinib pharmacokinetics, relative to the pharmacokinetics in patients with normal renal function (CLcr ≥90 mL/min; N=567). The pharmacokinetics of dacomitinib has not been adequately characterized in patients with severe renal impairment (CLcr <30 mL/min) (N=4) or studied in patients requiring hemodialysis. Patients with Hepatic Impairment No clinically significant differences in the pharmacokinetics of dacomitinib were observed in subjects with mild, moderate or severe hepatic impairment (Child-Pugh A, B or C) [see Use in Specific Populations (8.7) ]. Drug Interaction Studies Clinical Studies Effect of Acid-Reducing Agents on Dacomitinib Coadministration of a single 45 mg dose of VIZIMPRO with multiple doses of rabeprazole (a proton pump inhibitor) decreased dacomitinib C max by 51% and AUC 0–96h by 39% [see Dosage and Administration (2.4) and Drug Interactions (7.1) ]. Coadministration of VIZIMPRO with a local antacid (Maalox ® Maximum Strength, 400 mg/5 mL) did not cause clinically relevant changes dacomitinib concentrations [see Dosage and Administration (2.4) and Drug Interactions (7.1) ] . The effect of H2 receptor antagonists on dacomitinib pharmacokinetics has not been studied [see Dosage and Administration (2.4) and Drug Interactions (7.1) ] . Effect of Strong CYP2D6 Inhibitors on Dacomitinib Coadministration of a single 45 mg dose of VIZIMPRO with multiple doses of paroxetine (a strong CYP2D6 inhibitor) in healthy subjects increased the total AUC last of dacomitinib plus its active metabolite (O-desmethyl dacomitinib) in plasma by approximately 6%, which is not considered clinically relevant. Effect of Dacomitinib on CYP2D6 Substrates Coadministration of a single 45 mg oral dose of VIZIMPRO increased dextromethorphan (a CYP2D6 substrate) C max by 9.7-fold and AUC last by 9.6-fold [see Drug Interactions (7.2) ] . In Vitro Studies Effect of Dacomitinib and O-desmethyl Dacomitinib on CYP Enzymes: Dacomitinib and its metabolite O-desmethyl dacomitinib do not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP3A4/5. Dacomitinib does not induce CYP1A2, CYP2B6, or CYP3A4. Effect of Dacomitinib on Uridine 5' diphospho-glucuronosyltransferase (UGT) Enzymes: Dacomitinib inhibits UGT1A1. Dacomitinib does not inhibit UGT1A4, UGT1A6, UGT1A9, UGT2B7, or UGT2B15. Effect of Dacomitinib on Transporter Systems: Dacomitinib is a substrate for the membrane transport protein P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP). Dacomitinib inhibits P-gp, BCRP, and organic cation transporter (OCT)1. Dacomitinib does not inhibit organic anion transporters (OAT)1 and OAT3, OCT2, organic anion transporting polypeptide (OATP)1B1, and OATP1B3."],"adverse_reactions":["6 ADVERSE REACTIONS The following adverse drug reactions are described elsewhere in the labeling: • Interstitial Lung Disease [see Warnings and Precautions (5.1) ] • Diarrhea [see Warnings and Precautions (5.2) ] • Dermatologic Adverse Reactions [see Warnings and Precautions (5.3) ] Most common adverse reactions (incidence >20%) are diarrhea, rash, paronychia, stomatitis, decreased appetite, dry skin, decreased weight, alopecia, cough, and pruritus. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The data in the Warnings and Precautions section reflect exposure to VIZIMPRO in 394 patients with first-line or previously treated NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution mutations who received VIZIMPRO at the recommended dose of 45 mg once daily in 4 randomized, active-controlled trials [ARCHER 1050 (N=227), Study A7471009 (N=38), Study A7471011 (N=83), and Study A7471028 (N=16)] and one single-arm trial [Study A7471017 (N=30)]. The median duration of exposure to VIZIMPRO was 10.8 months (range 0.07–68) [see Warnings and Precautions (5) ]. The data described below reflect exposure to VIZIMPRO in 227 patients with EGFR mutation-positive, metastatic NSCLC enrolled in a randomized, active-controlled trial (ARCHER 1050 ) ; 224 patients received gefitinib 250 mg orally once daily in the active control arm [see Clinical Studies (14) ] . Patients were excluded if they had a history of ILD, interstitial pneumonitis, or brain metastases. The median duration of exposure to VIZIMPRO was 15 months (range 0.07–37). The most common (>20%) adverse reactions in patients treated with VIZIMPRO were diarrhea (87%), rash (69%), paronychia (64%), stomatitis (45%), decreased appetite (31%), dry skin (30%), decreased weight (26%), alopecia (23%), cough (21%), and pruritus (21%). Serious adverse reactions occurred in 27% of patients treated with VIZIMPRO. The most common (≥1%) serious adverse reactions were diarrhea (2.2%) and interstitial lung disease (1.3%). Dose interruptions occurred in 57% of patients treated with VIZIMPRO. The most frequent (>5%) adverse reactions leading to dose interruptions were rash (23%), paronychia (13%), and diarrhea (10%). Dose reductions occurred in 66% of patients treated with VIZIMPRO. The most frequent (>5%) adverse reactions leading to dose reductions were rash (29%), paronychia (17%), and diarrhea (8%). Adverse reactions leading to permanent discontinuation of VIZIMPRO occurred in 18% of patients. The most common (>0.5%) adverse reactions leading to permanent discontinuation of VIZIMPRO were: rash (2.6%), interstitial lung disease (1.8%), stomatitis (0.9%), and diarrhea (0.9%). Tables 3 and 4 summarize the most common adverse reactions and laboratory abnormalities, respectively, in ARCHER 1050. ARCHER 1050 was not designed to demonstrate a statistically significant difference in adverse reaction rates for VIZIMPRO or for gefitinib for any adverse reaction or laboratory value listed in Table 3 or 4. Table 3. Adverse Reactions Occurring in ≥10% of Patients Receiving VIZIMPRO in ARCHER 1050 National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03. Adverse Reaction VIZIMPRO (N=227) Gefitinib (N=224) All Grades Grades 1 through 5 are included in All Grades. % Grades 3 and 4 % All Grades % Grades 3 and 4 % Gastrointestinal Diarrhea One Grade 5 (fatal) event in the VIZIMPRO arm. 87 8 56 0.9 Stomatitis Stomatitis includes mucosal inflammation and stomatitis. 45 4.4 19 0.4 Nausea 19 1.3 22 0.4 Constipation 13 0 14 0 Mouth ulceration 12 0 6 0 Skin and Subcutaneous Tissue Rash Rash includes dermatitis acneiform, rash, and rash maculo-papular. 69 23 47 0.4 Paronychia Paronychia includes nail infection, nail toxicity, onychoclasis, onycholysis, onychomadesis, paronychia. 64 8 21 1.3 Dry skin Dry skin includes dry skin, xerosis. 30 1.8 19 0.4 Alopecia 23 0.4 13 0 Pruritus Pruritus includes pruritus, pruritus generalized, rash pruritic. 21 0.9 15 1.3 Palmar-plantar erythrodysesthesia syndrome 15 0.9 3.1 0 Dermatitis 11 1.8 4 0.4 Metabolism and Nutrition Decreased appetite 31 3.1 25 0.4 Decreased weight 26 2.2 17 0.4 Respiratory Cough 21 0 19 0.4 Nasal mucosal disorder Nasal mucosal disorder includes epistaxis, nasal inflammation, nasal mucosal disorder, nasal mucosal ulcer, rhinitis. 19 0 4.9 0 Dyspnea 13 2.2 13 1.8 Upper respiratory tract infection 12 1.3 13 0 Chest pain 10 0 14 0 Eye Conjunctivitis 19 0 4 0 Musculoskeletal Pain in extremity 14 0 12 0 Musculoskeletal pain 12 0.9 13 0 General Asthenia 13 2.2 13 1.3 Psychiatric Insomnia 11 0.4 15 0 Additional adverse reactions (All Grades) that were reported in <10% of patients who received VIZIMPRO in ARCHER 1050 include: General : fatigue 9% Skin and subcutaneous tissue : skin fissures 9%, hypertrichosis 1.3%, skin exfoliation/exfoliative skin reactions 3.5% Gastrointestinal : vomiting 9% Nervous system : dysgeusia 7% Respiratory: interstitial lung disease 2.6% Ocular: keratitis 1.8% Metabolism and nutrition : dehydration 1.3% Table 4. Laboratory Abnormalities Worsening from Baseline in >20% of Patients in ARCHER 1050 NCI CTCAE v4.03, except for increased creatinine which only includes patients with creatinine increase based on upper limit of normal definition. Laboratory Test Abnormality Based on the number of patients with available baseline and at least one on-treatment laboratory test. VIZIMPRO Gefitinib Change from Baseline All Grades (%) Change from Baseline to Grade 3 or Grade 4 (%) Change from Baseline All Grades (%) Change from Baseline to Grade 3 or Grade 4 (%) ALT=alanine aminotransferase; AST=aspartate aminotransferase. Hematology Anemia 44 0.9 26 2.7 Lymphopenia 42 6 35 2.7 Chemistry Hypoalbuminemia 44 0 34 0 Increased ALT 40 1.4 63 13 Hyperglycemia 36 1.0 38 2.5 Increased AST 35 0.5 57 8 Hypocalcemia 33 1.4 28 2.0 Hypokalemia 29 7 18 2.0 Hyponatremia 26 2.9 20 1.5 Increased creatinine 24 0 16 0.5 Increased alkaline phosphatase 22 0.5 21 2.0 Hypomagnesemia 22 0.5 9 0 Hyperbilirubinemia 16 0.5 22 0.5"],"contraindications":["4 CONTRAINDICATIONS None. None. ( 4 )"],"drug_interactions":["7 DRUG INTERACTIONS • Proton Pump Inhibitors (PPIs): Avoid use with VIZIMPRO; use locally-acting antacids or H2-receptor antagonist; administer VIZIMPRO at least 6 hours before or 10 hours after H2-receptor antagonist. ( 2.4 , 7.1 ) • CYP2D6 Substrates: Avoid concomitant use with VIZIMPRO where minimal increases in concentration of the CYP2D6 substrate may lead to serious or life-threatening toxicities. ( 7.2 ) 7.1 Effect of Other Drugs on VIZIMPRO Concomitant use with a PPI decreases dacomitinib concentrations, which may reduce VIZIMPRO efficacy. Avoid the concomitant use of PPIs with VIZIMPRO. As an alternative to PPIs, use locally-acting antacids or an H2-receptor antagonist. Administer VIZIMPRO at least 6 hours before or 10 hours after taking an H2-receptor antagonist [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3) ] . 7.2 Effect of VIZIMPRO on CYP2D6 Substrates Concomitant use of VIZIMPRO increases the concentration of drugs that are CYP2D6 substrates [see Clinical Pharmacology (12.3) ] which may increase the risk of toxicities of these drugs. Avoid concomitant use of VIZIMPRO with CYP2D6 substrates where minimal increases in concentration of the CYP2D6 substrate may lead to serious or life-threatening toxicities."],"how_supplied_table":["
Table 6. VIZIMPRO Strengths and Package Configurations
VIZIMPRO Tablets
Package ConfigurationTablet Strength (mg)NDCTablet Description
30-Count Bottle with a child-resistant closure150069-0197-30Blue film-coated, immediate release, round biconvex tablet, debossed with "Pfizer" on one side and "DCB15" on the other side.
30-Count Bottle with a child-resistant closure300069-1198-30Blue film-coated immediate release, round biconvex tablet, debossed with "Pfizer" on one side and "DCB30" on the other side.
30-Count Bottle with a child-resistant closure450069-2299-30Blue film-coated immediate release, round biconvex tablet, debossed with "Pfizer" on one side and "DCB45" on the other side.
"],"mechanism_of_action":["12.1 Mechanism of Action Dacomitinib is an irreversible inhibitor of the kinase activity of the human EGFR family (EGFR/HER1, HER2, and HER4) and certain EGFR activating mutations (exon 19 deletion or the exon 21 L858R substitution mutation). In vitro dacomitinib also inhibited the activity of DDR1, EPHA6, LCK, DDR2, and MNK1 at clinically relevant concentrations. Dacomitinib demonstrated dose-dependent inhibition of EGFR and HER2 autophosphorylation and tumor growth in mice bearing subcutaneously implanted human tumor xenografts driven by HER family targets including mutated EGFR. Dacomitinib also exhibited antitumor activity in orally-dosed mice bearing intracranial human tumor xenografts driven by EGFR amplifications."],"storage_and_handling":["Store at 20 °C to 25 °C (68 °F to 77 °F); excursions permitted between 15 °C to 30 °C (59 °F to 86 °F). [see USP Controlled Room Temperature]."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Dacomitinib is an irreversible inhibitor of the kinase activity of the human EGFR family (EGFR/HER1, HER2, and HER4) and certain EGFR activating mutations (exon 19 deletion or the exon 21 L858R substitution mutation). In vitro dacomitinib also inhibited the activity of DDR1, EPHA6, LCK, DDR2, and MNK1 at clinically relevant concentrations. Dacomitinib demonstrated dose-dependent inhibition of EGFR and HER2 autophosphorylation and tumor growth in mice bearing subcutaneously implanted human tumor xenografts driven by HER family targets including mutated EGFR. Dacomitinib also exhibited antitumor activity in orally-dosed mice bearing intracranial human tumor xenografts driven by EGFR amplifications. 12.2 Pharmacodynamics Cardiac Electrophysiology The effect of dacomitinib on the QT interval corrected for heart rate (QTc) was evaluated using time-matched electrocardiograms (ECGs) evaluating the change from baseline and corresponding pharmacokinetic data in 32 patients with advanced NSCLC. Dacomitinib had no large effect on QTc (i.e., >20 ms) at maximum dacomitinib concentrations achieved with VIZIMPRO 45 mg orally once daily. Exposure-Response Relationships Higher exposures, across the range of exposures with the recommended dose of 45 mg daily, correlated with an increased probability of Grade ≥3 adverse events, specifically dermatologic toxicities and diarrhea. 12.3 Pharmacokinetics The maximum dacomitinib plasma concentration (C max ) and AUC at steady state increased proportionally over the dose range of VIZIMPRO 2 mg to 60 mg orally once daily (0.04 to 1.3 times the recommended dose) across dacomitinib studies in patients with cancer. At a dose of 45 mg orally once daily, the geometric mean [coefficient of variation (CV%)] C max was 108 ng/mL (35%) and the AUC 0–24h was 2213 ng∙h/mL (35%) at steady state in a dose-finding clinical study conducted in patients with solid tumors. Steady state was achieved within 14 days following repeated dosing and the estimated geometric mean (CV%) accumulation ratio was 5.7 (28%) based on AUC. Absorption The mean absolute bioavailability of dacomitinib is 80% after oral administration. The median dacomitinib time to reach maximum concentration (T max ) occurred at approximately 6.0 hours (range 2.0 to 24 hours) after a single oral dose of VIZIMPRO 45 mg in patients with cancer. Effect of Food Administration of VIZIMPRO with a high-fat, high-calorie meal (approximately 800 to 1000 calories with 150, 250, and 500 to 600 calories from protein, carbohydrate and fat, respectively) had no clinically meaningful effect on dacomitinib pharmacokinetics. Distribution The geometric mean (CV%) volume of distribution of dacomitinib (V ss ) was 1889 L (18%). In vitro binding of dacomitinib to human plasma proteins is approximately 98% and is independent of drug concentrations from 250 ng/mL to 1000 ng/mL. Elimination Following a single 45 mg oral dose of VIZIMPRO in patients with cancer, the mean (CV%) plasma half-life of dacomitinib was 70 hours (21%), and the geometric mean (CV%) apparent plasma clearance of dacomitinib was 24.9 L/h (36%). Metabolism Hepatic metabolism is the main route of clearance of dacomitinib, with oxidation and glutathione conjugation as the major pathways. Following oral administration of a single 45 mg dose of [ 14 C] dacomitinib, the most abundant circulating metabolite was O-desmethyl dacomitinib, which had similar in vitro pharmacologic activity as dacomitinib. The steady-state plasma trough concentration of O-desmethyl dacomitinib ranges from 7.4% to 19% of the parent. In vitro studies indicated that cytochrome P450 (CYP) 2D6 was the major isozyme involved in the formation of O-desmethyl dacomitinib, while CYP3A4 contributed to the formation of other minor oxidative metabolites. Excretion Following a single oral 45 mg dose of [ 14 C] radiolabeled dacomitinib, 79% of the radioactivity was recovered in feces (20% as dacomitinib) and 3% in urine (<1% as dacomitinib). Specific Populations Patients with Renal Impairment Based on population pharmacokinetic analyses, mild (60 mL/min ≤CLcr <90 mL/min; N=590) and moderate (30 mL/min ≤CLcr <60 mL/min; N=218) renal impairment did not alter dacomitinib pharmacokinetics, relative to the pharmacokinetics in patients with normal renal function (CLcr ≥90 mL/min; N=567). The pharmacokinetics of dacomitinib has not been adequately characterized in patients with severe renal impairment (CLcr <30 mL/min) (N=4) or studied in patients requiring hemodialysis. Patients with Hepatic Impairment No clinically significant differences in the pharmacokinetics of dacomitinib were observed in subjects with mild, moderate or severe hepatic impairment (Child-Pugh A, B or C) [see Use in Specific Populations (8.7) ]. Drug Interaction Studies Clinical Studies Effect of Acid-Reducing Agents on Dacomitinib Coadministration of a single 45 mg dose of VIZIMPRO with multiple doses of rabeprazole (a proton pump inhibitor) decreased dacomitinib C max by 51% and AUC 0–96h by 39% [see Dosage and Administration (2.4) and Drug Interactions (7.1) ]. Coadministration of VIZIMPRO with a local antacid (Maalox ® Maximum Strength, 400 mg/5 mL) did not cause clinically relevant changes dacomitinib concentrations [see Dosage and Administration (2.4) and Drug Interactions (7.1) ] . The effect of H2 receptor antagonists on dacomitinib pharmacokinetics has not been studied [see Dosage and Administration (2.4) and Drug Interactions (7.1) ] . Effect of Strong CYP2D6 Inhibitors on Dacomitinib Coadministration of a single 45 mg dose of VIZIMPRO with multiple doses of paroxetine (a strong CYP2D6 inhibitor) in healthy subjects increased the total AUC last of dacomitinib plus its active metabolite (O-desmethyl dacomitinib) in plasma by approximately 6%, which is not considered clinically relevant. Effect of Dacomitinib on CYP2D6 Substrates Coadministration of a single 45 mg oral dose of VIZIMPRO increased dextromethorphan (a CYP2D6 substrate) C max by 9.7-fold and AUC last by 9.6-fold [see Drug Interactions (7.2) ] . In Vitro Studies Effect of Dacomitinib and O-desmethyl Dacomitinib on CYP Enzymes: Dacomitinib and its metabolite O-desmethyl dacomitinib do not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP3A4/5. Dacomitinib does not induce CYP1A2, CYP2B6, or CYP3A4. Effect of Dacomitinib on Uridine 5' diphospho-glucuronosyltransferase (UGT) Enzymes: Dacomitinib inhibits UGT1A1. Dacomitinib does not inhibit UGT1A4, UGT1A6, UGT1A9, UGT2B7, or UGT2B15. Effect of Dacomitinib on Transporter Systems: Dacomitinib is a substrate for the membrane transport protein P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP). Dacomitinib inhibits P-gp, BCRP, and organic cation transporter (OCT)1. Dacomitinib does not inhibit organic anion transporters (OAT)1 and OAT3, OCT2, organic anion transporting polypeptide (OATP)1B1, and OATP1B3."],"indications_and_usage":["1 INDICATIONS AND USAGE VIZIMPRO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test [see Dosage and Administration (2.1) ] . VIZIMPRO is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test. ( 1 )"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS • Interstitial Lung Disease (ILD): Permanently discontinue VIZIMPRO if ILD is confirmed. ( 5.1 ) • Diarrhea: Withhold and reduce the dose of VIZIMPRO based on the severity. ( 2.3 , 5.2 ) • Dermatologic Adverse Reactions: Withhold and reduce the dose of VIZIMPRO based on the severity. ( 2.3 , 5.3 ) • Embryo-Fetal Toxicity: VIZIMPRO can cause fetal harm. Advise females of reproductive potential to use effective contraception. ( 5.4 , 8.1 , 8.3 ) 5.1 Interstitial Lung Disease (ILD) Severe and fatal ILD/pneumonitis occurred in patients treated with VIZIMPRO and occurred in 0.5% of the 394 VIZIMPRO-treated patients; 0.3% of cases were fatal. Monitor patients for pulmonary symptoms indicative of ILD/pneumonitis. Withhold VIZIMPRO and promptly investigate for ILD in patients who present with worsening of respiratory symptoms which may be indicative of ILD (e.g., dyspnea, cough, and fever). Permanently discontinue VIZIMPRO if ILD is confirmed [see Adverse Reactions (6.1) ] . 5.2 Diarrhea Severe and fatal diarrhea occurred in patients treated with VIZIMPRO. Diarrhea occurred in 86% of the 394 VIZIMPRO-treated patients; Grade 3 or 4 diarrhea was reported in 11% of patients and 0.3% of cases were fatal. Withhold VIZIMPRO for Grade 2 or greater diarrhea until recovery to less than or equal to Grade 1 severity, then resume VIZIMPRO at the same or a reduced dose depending on the severity of diarrhea [see Dosage and Administration (2.3) and Adverse Reactions (6.1) ]. Promptly initiate anti-diarrheal treatment (loperamide or diphenoxylate hydrochloride with atropine sulfate) for diarrhea. 5.3 Dermatologic Adverse Reactions Rash and exfoliative skin reactions occurred in patients treated with VIZIMPRO. Rash occurred in 78% of the 394 VIZIMPRO-treated patients; Grade 3 or 4 rash was reported in 21% of patients. Exfoliative skin reactions of any severity were reported in 7% of patients. Grade 3 or 4 exfoliative skin reactions were reported in 1.8% of patients. Withhold VIZIMPRO for persistent Grade 2 or any Grade 3 or 4 dermatologic adverse reaction until recovery to less than or equal to Grade 1 severity, then resume VIZIMPRO at the same or a reduced dose depending on the severity of the dermatologic adverse reaction [see Dosage and Administration (2.3) and Adverse Reactions (6.1) ]. The incidence and severity of rash and exfoliative skin reactions may increase with sun exposure. At the time of initiation of VIZIMPRO, initiate use of moisturizers and appropriate measures to limit sun exposure. Upon development of Grade 1 rash, initiate treatment with topical antibiotics and topical steroids. Initiate oral antibiotics for Grade 2 or more severe dermatologic adverse reactions. 5.4 Embryo-Fetal Toxicity Based on findings from animal studies and its mechanism of action, VIZIMPRO can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, oral administration of dacomitinib to pregnant rats during the period of organogenesis resulted in an increased incidence of post-implantation loss and reduced fetal body weight at doses resulting in exposures near the exposure at the 45 mg human dose. The absence of EGFR signaling has been shown to result in embryolethality as well as post-natal death in animals. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with VIZIMPRO and for at least 17 days after the final dose [see Use in Specific Populations (8.1 and 8.3) ] ."],"clinical_studies_table":["
Table 5. Efficacy Results in ARCHER 1050
VIZIMPRO N=227Gefitinib N=225
CI=confidence interval; DoR=duration of response; HR=hazard ratio; IRC=Independent Radiologic Central; N/n=total number; PFS=progression-free survival.
Progression-Free Survival (per IRC)
Number of patients with event, n (%)136 (59.9%)179 (79.6%)
Median PFS in months (95% CI)14.7 (11.1, 16.6)9.2 (9.1, 11.0)
HR (95% CI)From stratified Cox Regression.0.59 (0.47, 0.74)
p-valueBased on the stratified log-rank test. <0.0001
Overall Response Rate (per IRC)
Overall Response Rate % (95% CI)75% (69, 80)72% (65, 77)
p-valueBased on the stratified Cochran-Mantel-Haenszel test.0.39
Duration of Response in Responders (per IRC)
Median DoR in months (95% CI)14.8 (12.0, 17.4)8.3 (7.4, 9.2)
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity studies have not been performed with VIZIMPRO. Dacomitinib was not mutagenic in a bacterial reverse mutation (Ames) assay or clastogenic in an in vitro human lymphocyte chromosome aberration assay or clastogenic or aneugenic in an in vivo rat bone marrow micronucleus assay. Daily oral administration of dacomitinib at doses ≥0.5 mg/kg/day to female rats (approximately 0.14 times the exposure based on AUC at the 45 mg human dose) resulted in reversible epithelial atrophy in the cervix and vagina. Oral administration of dacomitinib at 2 mg/kg/day to male rats (approximately 0.6 times the human exposure based on AUC at the 45 mg clinical dose) resulted in reversible decreased secretion in the prostate gland."],"adverse_reactions_table":["
Table 3. Adverse Reactions Occurring in ≥10% of Patients Receiving VIZIMPRO in ARCHER 1050National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03.
Adverse ReactionVIZIMPRO (N=227)Gefitinib (N=224)
All GradesGrades 1 through 5 are included in All Grades. %Grades 3 and 4 %All Grades %Grades 3 and 4 %
Gastrointestinal
DiarrheaOne Grade 5 (fatal) event in the VIZIMPRO arm.878560.9
StomatitisStomatitis includes mucosal inflammation and stomatitis.454.4190.4
Nausea191.3220.4
Constipation130140
Mouth ulceration12060
Skin and Subcutaneous Tissue
RashRash includes dermatitis acneiform, rash, and rash maculo-papular.6923470.4
ParonychiaParonychia includes nail infection, nail toxicity, onychoclasis, onycholysis, onychomadesis, paronychia.648211.3
Dry skinDry skin includes dry skin, xerosis.301.8190.4
Alopecia230.4130
PruritusPruritus includes pruritus, pruritus generalized, rash pruritic.210.9151.3
Palmar-plantar erythrodysesthesia syndrome150.93.10
Dermatitis111.840.4
Metabolism and Nutrition
Decreased appetite313.1250.4
Decreased weight262.2170.4
Respiratory
Cough210190.4
Nasal mucosal disorderNasal mucosal disorder includes epistaxis, nasal inflammation, nasal mucosal disorder, nasal mucosal ulcer, rhinitis.1904.90
Dyspnea132.2131.8
Upper respiratory tract infection121.3130
Chest pain100140
Eye
Conjunctivitis19040
Musculoskeletal
Pain in extremity140120
Musculoskeletal pain120.9130
General
Asthenia132.2131.3
Psychiatric
Insomnia110.4150
","
Table 4. Laboratory Abnormalities Worsening from Baseline in >20% of Patients in ARCHER 1050NCI CTCAE v4.03, except for increased creatinine which only includes patients with creatinine increase based on upper limit of normal definition.
Laboratory Test AbnormalityBased on the number of patients with available baseline and at least one on-treatment laboratory test.VIZIMPROGefitinib
Change from Baseline All Grades (%)Change from Baseline to Grade 3 or Grade 4 (%)Change from Baseline All Grades (%)Change from Baseline to Grade 3 or Grade 4 (%)
ALT=alanine aminotransferase; AST=aspartate aminotransferase.
Hematology
Anemia440.9262.7
Lymphopenia426352.7
Chemistry
Hypoalbuminemia440340
Increased ALT401.46313
Hyperglycemia361.0382.5
Increased AST350.5578
Hypocalcemia331.4282.0
Hypokalemia297182.0
Hyponatremia262.9201.5
Increased creatinine240160.5
Increased alkaline phosphatase220.5212.0
Hypomagnesemia220.590
Hyperbilirubinemia160.5220.5
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information). Interstitial Lung Disease (ILD) • Advise patients of the risks of severe or fatal ILD, including pneumonitis. Advise patients to contact their healthcare provider immediately to report new or worsening respiratory symptoms [see Warnings and Precautions (5.1) ] . Diarrhea • Advise patients to contact their healthcare provider at the first signs of diarrhea. Advise patients that intravenous hydration and/or anti-diarrheal medication (e.g., loperamide) may be required to manage diarrhea [see Warnings and Precautions (5.2) ] . Dermatologic Adverse Reactions • Advise patients to initiate use of moisturizers and to minimize sun exposure with protective clothing and use of sunscreen at the time of initiation of VIZIMPRO. Advise patients to contact their healthcare provider immediately to report new or worsening rash, erythematous and exfoliative reactions [see Warning and Precautions (5.3) ]. Drug Interactions • Advise patients to avoid use of PPIs while taking VIZIMPRO. Short-acting antacids or H2 receptor antagonists may be used if needed. Advise patients to take VIZIMPRO at least 6 hours before or 10 hours after taking an H2-receptor antagonist [see Drug Interactions (7.1) ]. Embryo-Fetal Toxicity • Advise females of reproductive potential that VIZIMPRO can result in fetal harm and to use effective contraception during treatment with VIZIMPRO and for 17 days after the last dose of VIZIMPRO. Advise females of reproductive potential to contact their healthcare provider with a known or suspected pregnancy [see Use in Specific Populations (8.1 and 8.3) ]. Lactation • Advise women not to breastfeed during treatment with VIZIMPRO and for 17 days after the last dose of VIZIMPRO [see Use in Specific Populations (8.2) ] ."],"spl_unclassified_section":["This product's labeling may have been updated. For the most recent prescribing information, please visit www.VIZIMPRO.com. LAB-1237-2.0 Logo"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Recommended Dosage: 45 mg orally once daily with or without food. ( 2.2 ) 2.1 Patient Selection Select patients for the first-line treatment of metastatic NSCLC with VIZIMPRO based on the presence of an EGFR exon 19 deletion or exon 21 L858R substitution mutation in tumor specimens. Information on FDA-approved tests for the detection of EGFR mutations in NSCLC is available at: http://www.fda.gov/CompanionDiagnostics. 2.2 Recommended Dosage The recommended dosage of VIZIMPRO is 45 mg taken orally once daily, until disease progression or unacceptable toxicity occurs. VIZIMPRO can be taken with or without food [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3) ] . Take VIZIMPRO the same time each day. If the patient vomits or misses a dose, do not take an additional dose or make up a missed dose but continue with the next scheduled dose. 2.3 Dosage Modifications for Adverse Reactions Reduce the dose of VIZIMPRO for adverse reactions as described in Table 1. Dosage modifications for specific adverse reactions are provided in Table 2. Table 1. VIZIMPRO Recommended Dose Reductions for Adverse Reactions Dose Level Dose (Once Daily) First dose reduction 30 mg Second dose reduction 15 mg Table 2. VIZIMPRO Dosage Modifications for Adverse Reactions Adverse Reaction Severity National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03. Dosage Modification Interstitial lung disease (ILD) [see Warnings and Precautions (5.1) ] Any Grade • Permanently discontinue VIZIMPRO. Diarrhea [see Warnings and Precautions (5.2) ] Grade 2 • Withhold VIZIMPRO until recovery to less than or equal to Grade 1; then resume VIZIMPRO at the same dose level. • For recurrent Grade 2 diarrhea, withhold until recovery to less than or equal to Grade 1; then resume VIZIMPRO at a reduced dose. Grade 3 or 4 • Withhold VIZIMPRO until recovery to less than or equal to Grade 1; then resume VIZIMPRO at a reduced dose. Dermatologic Adverse Reactions [see Warnings and Precautions (5.3) ] Grade 2 • Withhold VIZIMPRO for persistent dermatologic adverse reactions; upon recovery to less than or equal to Grade 1, resume VIZIMPRO at the same dose level. • For recurrent persistent Grade 2 dermatologic adverse reactions, withhold until recovery to less than or equal to Grade 1; then resume VIZIMPRO at a reduced dose. Grade 3 or 4 • Withhold VIZIMPRO until recovery to less than or equal to Grade 1; then resume VIZIMPRO at a reduced dose. Other Grade 3 or 4 • Withhold VIZIMPRO until recovery to less than or equal to Grade 2; then resume VIZIMPRO at a reduced dose. 2.4 Dosage Modifications for Acid-Reducing Agents Avoid the concomitant use of proton pump inhibitors (PPIs) while taking VIZIMPRO. As an alternative to PPIs, use locally-acting antacids or if using an histamine 2 (H2)-receptor antagonist, administer VIZIMPRO at least 6 hours before or 10 hours after taking an H2-receptor antagonist [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] ."],"spl_product_data_elements":["Vizimpro dacomitinib DACOMITINIB DACOMITINIB ANHYDROUS LACTOSE MONOHYDRATE MICROCRYSTALLINE CELLULOSE SODIUM STARCH GLYCOLATE TYPE A POTATO MAGNESIUM STEARATE POLYVINYL ALCOHOL, UNSPECIFIED TALC TITANIUM DIOXIDE POLYETHYLENE GLYCOL 3350 FD&C BLUE NO. 2 Pfizer;DCB15 Vizimpro dacomitinib DACOMITINIB DACOMITINIB ANHYDROUS LACTOSE MONOHYDRATE MICROCRYSTALLINE CELLULOSE SODIUM STARCH GLYCOLATE TYPE A POTATO MAGNESIUM STEARATE POLYVINYL ALCOHOL, UNSPECIFIED TALC TITANIUM DIOXIDE POLYETHYLENE GLYCOL 3350 FD&C BLUE NO. 2 Pfizer;DCB30 Vizimpro dacomitinib DACOMITINIB DACOMITINIB ANHYDROUS LACTOSE MONOHYDRATE MICROCRYSTALLINE CELLULOSE SODIUM STARCH GLYCOLATE TYPE A POTATO MAGNESIUM STEARATE POLYVINYL ALCOHOL, UNSPECIFIED TALC TITANIUM DIOXIDE POLYETHYLENE GLYCOL 3350 FD&C BLUE NO. 2 Pfizer;DCB45"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Tablets: • 45 mg: blue film-coated, immediate release, round biconvex tablet, debossed with \"Pfizer\" on one side and \"DCB45\" on the other side. • 30 mg: blue film-coated, immediate release, round biconvex tablet, debossed with \"Pfizer\" on one side and \"DCB30\" on the other side. • 15 mg: blue film-coated, immediate release, round biconvex tablet, debossed with \"Pfizer\" on one side and \"DCB15\" on the other side. Tablets: 15 mg, 30 mg, and 45 mg. ( 3 )"],"spl_patient_package_insert":["PATIENT INFORMATION VIZIMPRO ® ( vih-ZIM-pro ) (dacomitinib) tablets What is VIZIMPRO? VIZIMPRO is a prescription medicine used to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic): • As your first treatment if your tumor has certain types of abnormal epidermal growth factor receptor (EGFR) gene(s). Your healthcare provider will perform a test to make sure that VIZIMPRO is right for you. It is not known if VIZIMPRO is safe and effective in children. Before taking VIZIMPRO, tell your healthcare provider about all your medical conditions, including if you: • have frequent diarrhea. • have a history of lung or breathing problems other than lung cancer. • are pregnant, or plan to become pregnant. VIZIMPRO can harm your unborn baby. Females who are able to become pregnant: o Your healthcare provider should do a pregnancy test before you start treatment with VIZIMPRO. o You should use effective birth control (contraception) during treatment and for at least 17 days after your last dose of VIZIMPRO. Talk to your healthcare provider about birth control methods that may be right for you during this time. o Tell your healthcare provider right away if you become pregnant during your treatment with VIZIMPRO. • are breastfeeding or plan to breastfeed. It is not known if VIZIMPRO passes into your breast milk. Do not breastfeed during treatment and for at least 17 days after your last dose of VIZIMPRO. Talk to your healthcare provider about the best way to feed your baby during this time. Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. VIZIMPRO and other medicines or supplements may affect each other causing side effects. How should I take VIZIMPRO? • Take VIZIMPRO exactly as your healthcare provider tells you. • Take your dose at approximately the same time each day. • Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with VIZIMPRO if you have side effects. • Take VIZIMPRO 1 time each day with or without food. • If you take an antacid or H2 blocker medicine during treatment with VIZIMPRO, take your dose of VIZIMPRO at least 6 hours before or 10 hours after taking the antacid or H2 blocker medicine. Do not change your dose or stop taking VIZIMPRO unless your healthcare provider tells you. • If you vomit or miss a dose of VIZIMPRO, do not take another dose or make up for the missed dose. Take your next dose at your regular time. What should I avoid during treatment with VIZIMPRO? • Minimize exposure to sunlight. VIZIMPRO can cause skin reactions. See “What are the possible side effects of VIZIMPRO?” What are the possible side effects of VIZIMPRO? VIZIMPRO may cause serious side effects, including: • Lung or breathing problems . VIZIMPRO may cause severe inflammation of the lung that may lead to death. Symptoms may be similar to those symptoms from lung cancer. Tell your healthcare provider right away if you have any new or worsening lung symptoms, including trouble breathing or shortness of breath, cough, or fever. • Diarrhea . Diarrhea is common during treatment with VIZIMPRO, and can be severe and lead to death. Diarrhea can cause you to lose too much body fluid (dehydration). Your healthcare provider may tell you to start drinking more fluids or start taking your anti-diarrheal medicines. Tell your healthcare provider right away, if you have any loose stools or have stools more often than is normal for you. • Skin reactions . Skin reactions are common with VIZIMPRO and can be severe. These skin reactions may include: dry skin, redness, rash, acne, itching, and peeling or blistering of your skin. Use moisturizers every day when taking VIZIMPRO. Use sunscreen and wear protective clothing that covers your skin, while exposed to sunlight, while you are taking VIZIMPRO. Your healthcare provider may prescribe other medicines to help skin reactions. Tell your healthcare provider right away about any worsening skin reactions. The most common side effects of VIZIMPRO include: • rash • diarrhea • mouth pain and sores • nail inflammation • common cold • dry skin • decreased appetite • decreased weight • dry, red, itchy eyes • hair loss • itching Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store VIZIMPRO? • Store VIZIMPRO at 20 °C to 25 °C (68 °F to 77 °F). Keep VIZIMPRO and all medicines out of the reach of children. General information about the safe and effective use of VIZIMPRO. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use VIZIMPRO for a condition for which it was not prescribed. Do not give VIZIMPRO to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or healthcare provider for more information about VIZIMPRO that is written for health professionals. What are the ingredients in VIZIMPRO? Active ingredient: dacomitinib Inactive ingredients: lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, and magnesium stearate. Film coating contains: Opadry II ® Blue 85F30716 containing: Polyvinyl alcohol – partially hydrolyzed, Talc, Titanium dioxide, Macrogol/PEG 3350, and FD&C Blue #2/Indigo Carmine Aluminum Lake. LAB-1238-1.0 For more information, go to www.VIZIMPRO.com or call 1-800-438-1985. This Patient Information has been approved by the U.S. Food and Drug Administration. Issued: September 2018 Logo"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS • Lactation: Advise not to breastfeed. ( 8.2 ) 8.1 Pregnancy Risk Summary Based on findings from animal studies and its mechanism of action, VIZIMPRO can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1) ] . There are no available data on VIZIMPRO use in pregnant women. In animal reproduction studies, oral administration of dacomitinib to pregnant rats during the period of organogenesis resulted in an increased incidence of post-implantation loss and reduced fetal body weight at doses resulting in exposures near the exposure at the 45 mg human dose (see Data) . The absence of EGFR signaling has been shown to result in embryolethality as well as post-natal death in animals (see Data) . Advise pregnant women of the potential risk to a fetus [see Use in Special Populations (8.3) ] . In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data Daily oral administration of dacomitinib to pregnant rats during the period of organogenesis resulted in an increased incidence of post-implantation loss, maternal toxicity, and reduced fetal body weight at 5 mg/kg/day (approximately 1.2 times the exposure based on area under the curve [AUC] at the 45 mg human dose). Disruption or depletion of EGFR in mouse models has shown EGFR is critically important in reproductive and developmental processes including blastocyst implantation, placental development, and embryo-fetal/post-natal survival and development. Reduction or elimination of embryo-fetal or maternal EGFR signaling in mice can prevent implantation, and can cause embryo-fetal loss during various stages of gestation (through effects on placental development), developmental anomalies, early death in surviving fetuses, and adverse developmental outcomes in multiple organs in embryos/neonates. 8.2 Lactation Risk Summary There is no information regarding the presence of dacomitinib or its metabolites in human milk or their effects on the breastfed infant or on milk production. Because of the potential for serious adverse reactions in breastfed infants from VIZIMPRO, advise women not to breastfeed during treatment with VIZIMPRO and for at least 17 days after the last dose. 8.3 Females and Males of Reproductive Potential Pregnancy Testing Verify the pregnancy status of females of reproductive potential prior to initiating VIZIMPRO [ see Use in Specific Populations (8.1) ]. Contraception VIZIMPRO can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1) ]. Females Advise females of reproductive potential to use effective contraception during treatment with VIZIMPRO and for at least 17 days after the final dose. 8.4 Pediatric Use The safety and effectiveness of VIZIMPRO in pediatrics have not been established. 8.5 Geriatric Use Of the total number of patients (N=394) in five clinical studies with EGFR mutation-positive NSCLC who received VIZIMPRO at a dose of 45 mg orally once daily [ARCHER 1050 (N=227), Study A7471009 (N=38), Study A7471011 (N=83), Study A7471028 (N=16), and Study A7471017 (N=30)] 40% were 65 years of age and older. Exploratory analyses across this population suggest a higher incidence of Grade 3 and 4 adverse reactions (67% versus 56%, respectively), more frequent dose interruptions (53% versus 45%, respectively), and more frequent discontinuations (24% versus 10%, respectively) for adverse reactions in patients 65 years or older as compared to those younger than 65 years. 8.6 Renal Impairment No dosage modification is recommended for patients with mild or moderate renal impairment (creatinine clearance [CLcr] 30 to 89 mL/min estimated by Cockcroft-Gault). The recommended dose of VIZIMPRO has not been established for patients with severe renal impairment (CLcr <30 mL/min) [see Clinical Pharmacology (12.3) ] . 8.7 Hepatic Impairment No dosage modification is recommended in patients with mild, moderate or severe hepatic impairment (Child-Pugh A, B or C) [see Clinical Pharmacology (12.3) ] ."],"dosage_and_administration_table":["
Table 1. VIZIMPRO Recommended Dose Reductions for Adverse Reactions
Dose LevelDose (Once Daily)
First dose reduction30 mg
Second dose reduction15 mg
","Permanently discontinue VIZIMPRO.Withhold VIZIMPRO until recovery to less than or equal to Grade 1; then resume VIZIMPRO at the same dose level.For recurrent Grade 2 diarrhea, withhold until recovery to less than or equal to Grade 1; then resume VIZIMPRO at a reduced dose.Withhold VIZIMPRO until recovery to less than or equal to Grade 1; then resume VIZIMPRO at a reduced dose.Withhold VIZIMPRO for persistent dermatologic adverse reactions; upon recovery to less than or equal to Grade 1, resume VIZIMPRO at the same dose level. For recurrent persistent Grade 2 dermatologic adverse reactions, withhold until recovery to less than or equal to Grade 1; then resume VIZIMPRO at a reduced dose.Withhold VIZIMPRO until recovery to less than or equal to Grade 1; then resume VIZIMPRO at a reduced dose.Withhold VIZIMPRO until recovery to less than or equal to Grade 2; then resume VIZIMPRO at a reduced dose.
Table 2. VIZIMPRO Dosage Modifications for Adverse Reactions
Adverse ReactionSeverityNational Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03. Dosage Modification
Interstitial lung disease (ILD) [see Warnings and Precautions (5.1)]Any Grade
•
Diarrhea [see Warnings and Precautions (5.2)]Grade 2
••
Grade 3 or 4
•
Dermatologic Adverse Reactions [see Warnings and Precautions (5.3)]Grade 2
••
Grade 3 or 4
•
OtherGrade 3 or 4
•
"],"spl_patient_package_insert_table":["As your first treatment if your tumor has certain types of abnormal epidermal growth factor receptor (EGFR) gene(s). Your healthcare provider will perform a test to make sure that VIZIMPRO is right for you. It is not known if VIZIMPRO is safe and effective in children.have frequent diarrhea.have a history of lung or breathing problems other than lung cancer.are pregnant, or plan to become pregnant. VIZIMPRO can harm your unborn baby.Females who are able to become pregnant:Your healthcare provider should do a pregnancy test before you start treatment with VIZIMPRO.You should use effective birth control (contraception) during treatment and for at least 17 days after your last dose of VIZIMPRO. Talk to your healthcare provider about birth control methods that may be right for you during this time.Tell your healthcare provider right away if you become pregnant during your treatment with VIZIMPRO.are breastfeeding or plan to breastfeed. It is not known if VIZIMPRO passes into your breast milk. Do not breastfeed during treatment and for at least 17 days after your last dose of VIZIMPRO. Talk to your healthcare provider about the best way to feed your baby during this time. Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. VIZIMPRO and other medicines or supplements may affect each other causing side effects.Take VIZIMPRO exactly as your healthcare provider tells you.Take your dose at approximately the same time each day.Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with VIZIMPRO if you have side effects.Take VIZIMPRO 1 time each day with or without food.If you take an antacid or H2 blocker medicine during treatment with VIZIMPRO, take your dose of VIZIMPRO at least 6 hours before or 10 hours after taking the antacid or H2 blocker medicine. Do not change your dose or stop taking VIZIMPRO unless your healthcare provider tells you.If you vomit or miss a dose of VIZIMPRO, do not take another dose or make up for the missed dose. Take your next dose at your regular time.Minimize exposure to sunlight. VIZIMPRO can cause skin reactions. See “What are the possible side effects of VIZIMPRO?”Lung or breathing problems. VIZIMPRO may cause severe inflammation of the lung that may lead to death. Symptoms may be similar to those symptoms from lung cancer. Tell your healthcare provider right away if you have any new or worsening lung symptoms, including trouble breathing or shortness of breath, cough, or fever.Diarrhea. Diarrhea is common during treatment with VIZIMPRO, and can be severe and lead to death. Diarrhea can cause you to lose too much body fluid (dehydration). Your healthcare provider may tell you to start drinking more fluids or start taking your anti-diarrheal medicines. Tell your healthcare provider right away, if you have any loose stools or have stools more often than is normal for you.Skin reactions. Skin reactions are common with VIZIMPRO and can be severe. These skin reactions may include: dry skin, redness, rash, acne, itching, and peeling or blistering of your skin. Use moisturizers every day when taking VIZIMPRO. Use sunscreen and wear protective clothing that covers your skin, while exposed to sunlight, while you are taking VIZIMPRO. Your healthcare provider may prescribe other medicines to help skin reactions. Tell your healthcare provider right away about any worsening skin reactions.The most common side effects of VIZIMPRO include:rashdiarrheamouth pain and soresnail inflammationcommon colddry skindecreased appetitedecreased weightdry, red, itchy eyeshair lossitchingStore VIZIMPRO at 20 °C to 25 °C (68 °F to 77 °F).Keep VIZIMPRO and all medicines out of the reach of children.
PATIENT INFORMATION VIZIMPRO® (vih-ZIM-pro) (dacomitinib) tablets
What is VIZIMPRO? VIZIMPRO is a prescription medicine used to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic):
•
Before taking VIZIMPRO, tell your healthcare provider about all your medical conditions, including if you:
••• ooo•
How should I take VIZIMPRO?
••••••
What should I avoid during treatment with VIZIMPRO?
•
What are the possible side effects of VIZIMPRO? VIZIMPRO may cause serious side effects, including:
•••
•••••
••••••
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store VIZIMPRO?
•
General information about the safe and effective use of VIZIMPRO. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use VIZIMPRO for a condition for which it was not prescribed. Do not give VIZIMPRO to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or healthcare provider for more information about VIZIMPRO that is written for health professionals.
What are the ingredients in VIZIMPRO? Active ingredient: dacomitinib Inactive ingredients: lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, and magnesium stearate. Film coating contains: Opadry II® Blue 85F30716 containing: Polyvinyl alcohol – partially hydrolyzed, Talc, Titanium dioxide, Macrogol/PEG 3350, and FD&C Blue #2/Indigo Carmine Aluminum Lake. LAB-1238-1.0 For more information, go to www.VIZIMPRO.com or call 1-800-438-1985.
This Patient Information has been approved by the U.S. Food and Drug Administration.Issued: September 2018
"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 15 mg Tablet Bottle Label Pfizer NDC 0069-0197-30 Vizimpro ® (dacomitinib) tablets 15 mg 30 Tablets Rx only PRINCIPAL DISPLAY PANEL - 15 mg Tablet Bottle Label","PRINCIPAL DISPLAY PANEL - 30 mg Tablet Bottle Label Pfizer NDC 0069-1198-30 Vizimpro ® (dacomitinib) tablets 30 mg 30 Tablets Rx only PRINCIPAL DISPLAY PANEL - 30 mg Tablet Bottle Label","PRINCIPAL DISPLAY PANEL - 45 mg Tablet Bottle Label Pfizer NDC 0069-2299-30 Vizimpro ® (dacomitinib) tablets 45 mg 30 Tablets Rx only PRINCIPAL DISPLAY PANEL - 45 mg Tablet Bottle Label"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity studies have not been performed with VIZIMPRO. Dacomitinib was not mutagenic in a bacterial reverse mutation (Ames) assay or clastogenic in an in vitro human lymphocyte chromosome aberration assay or clastogenic or aneugenic in an in vivo rat bone marrow micronucleus assay. Daily oral administration of dacomitinib at doses ≥0.5 mg/kg/day to female rats (approximately 0.14 times the exposure based on AUC at the 45 mg human dose) resulted in reversible epithelial atrophy in the cervix and vagina. Oral administration of dacomitinib at 2 mg/kg/day to male rats (approximately 0.6 times the human exposure based on AUC at the 45 mg clinical dose) resulted in reversible decreased secretion in the prostate gland."]},"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DEATH","source":"FDA FAERS","actionTaken":"234 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"116 reports"},{"date":"","signal":"RASH","source":"FDA FAERS","actionTaken":"112 reports"},{"date":"","signal":"NEOPLASM PROGRESSION","source":"FDA FAERS","actionTaken":"78 reports"},{"date":"","signal":"PARONYCHIA","source":"FDA FAERS","actionTaken":"57 reports"},{"date":"","signal":"BLOOD PRESSURE INCREASED","source":"FDA FAERS","actionTaken":"46 reports"},{"date":"","signal":"MALIGNANT NEOPLASM PROGRESSION","source":"FDA FAERS","actionTaken":"41 reports"},{"date":"","signal":"PRURITUS","source":"FDA FAERS","actionTaken":"35 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"34 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"31 reports"}],"drugInteractions":[{"drug":"Proton Pump Inhibitors (PPIs)","action":"Avoid","effect":"Decreases dacomitinib concentrations, which may reduce VIZIMPRO efficacy"},{"drug":"H2-receptor antagonists","action":"Adjust dose","effect":"May decrease dacomitinib concentrations"},{"drug":"Locally-acting antacids","action":"Monitor","effect":"Alternative to PPIs with minimal interaction"},{"drug":"CYP2D6 Substrates","action":"Avoid","effect":"VIZIMPRO increases concentration of CYP2D6 substrates, which may increase risk of serious or life-threatening toxicities"}],"commonSideEffects":[{"effect":"Diarrhea","drugRate":"87%","severity":"serious","_validated":true},{"effect":"Rash","drugRate":"69%","severity":"moderate","_validated":true},{"effect":"Paronychia","drugRate":"64%","severity":"moderate","_validated":true},{"effect":"Stomatitis","drugRate":"45%","severity":"moderate","_validated":true},{"effect":"Decreased appetite","drugRate":"31%","severity":"mild","_validated":true},{"effect":"Dry skin","drugRate":"30%","severity":"mild","_validated":true},{"effect":"Decreased weight","drugRate":"26%","severity":"moderate","_validated":true},{"effect":"Alopecia","drugRate":"23%","severity":"mild","_validated":true},{"effect":"Cough","drugRate":"21%","severity":"mild","_validated":true},{"effect":"Pruritus","drugRate":"21%","severity":"mild","_validated":true},{"effect":"Conjunctivitis","drugRate":"19%","severity":"mild","_validated":true},{"effect":"Nasal mucosal disorder","drugRate":"19%","severity":"mild","_validated":true},{"effect":"Nausea","drugRate":"19%","severity":"mild","_validated":true},{"effect":"Palmar-plantar erythrodysesthesia syndrome","drugRate":"15%","severity":"moderate","_validated":true},{"effect":"Pain in extremity","drugRate":"14%","severity":"mild","_validated":true},{"effect":"Dyspnea","drugRate":"13%","severity":"moderate","_validated":true},{"effect":"Constipation","drugRate":"13%","severity":"mild","_validated":true},{"effect":"Asthenia","drugRate":"13%","severity":"moderate","_validated":true},{"effect":"Interstitial lung disease","drugRate":"2.6%","severity":"serious","_validated":true}],"specialPopulations":{"Lactation":"Advise women not to breastfeed during treatment with VIZIMPRO and for at least 17 days after the last dose due to potential for serious adverse reactions in breastfed infants. No information available regarding presence of dacomitinib or metabolites in human milk.","Pregnancy":"VIZIMPRO can cause fetal harm when administered to a pregnant woman based on animal studies and mechanism of action. Animal reproduction studies showed oral administration of dacomitinib to pregnant rats during organogenesis resulted in increased post-implantation loss and reduced fetal body weight at doses near the 45 mg human dose. No available data on VIZIMPRO use in pregnant women. Advise pregnant women of potential risk to fetus. Background risk of major birth defects and miscarriage in U.S. general population is 2-4% and 15-20%, respectively.","Geriatric Use":"40% of patients in clinical studies were 65 years or older. Patients 65 years or older showed higher incidence of Grade 3 and 4 adverse reactions (67% versus 56%), more frequent dose interruptions (53% versus 45%), and more frequent discontinuations (24% versus 10%) compared to those younger than 65 years.","Pediatric Use":"Safety and effectiveness of VIZIMPRO in pediatrics have not been established.","Renal Impairment":"No dosage modification recommended for mild or moderate renal impairment (CLcr 30-89 mL/min). Recommended dose not established for severe renal impairment (CLcr <30 mL/min).","Hepatic Impairment":"No dosage modification recommended in patients with mild, moderate, or severe hepatic impairment (Child-Pugh A, B, or C).","Females and Males of Reproductive Potential":"Verify pregnancy status of females of reproductive potential prior to initiating VIZIMPRO. Advise females of reproductive potential to use effective contraception during treatment and for at least 17 days after final dose."}},"trials":[],"_chembl":null,"aliases":[],"patents":[{"applNo":"N211288","source":"FDA Orange Book","status":"Active","expires":"Feb 2, 2026","territory":"US","drugProduct":false,"patentNumber":"10603314","drugSubstance":false},{"applNo":"N211288","source":"FDA Orange Book","status":"Active","expires":"Feb 2, 2026","territory":"US","drugProduct":false,"patentNumber":"10596162","drugSubstance":false},{"applNo":"N211288","source":"FDA Orange Book","status":"Active","expires":"Sep 27, 2032","territory":"US","drugProduct":true,"patentNumber":"7772243","drugSubstance":true}],"pricing":[],"_fixedAt":"2026-03-30T11:24:09.878936","_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Dacomitinib","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:37:11.721494+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-19T23:37:11.721375+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Dacomitinib","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-19T23:37:18.771039+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:37:17.181172+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:37:11.794099+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-19T23:37:10.619612+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dacomitinib","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:37:17.526888+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:37:10.099508+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:37:10.099534+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-19T23:37:19.274200+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Receptor protein-tyrosine kinase erbB-4 inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:37:18.771002+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2105719/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:37:18.424497+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA211288","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:37:10.099538+00:00"}},"offLabel":[],"timeline":[{"date":"2018-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from PFIZER INC to Pfizer"},{"date":"2018-09-27","type":"positive","source":"DrugCentral","milestone":"FDA approval (Pfizer Inc)"},{"date":"2019-02-04","type":"positive","source":"DrugCentral","milestone":"EMA approval (Pfizer Europe Ma Eeig)"},{"date":"2019-08-01","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Pfizer Japan Inc.)"},{"date":"2032-09-27","type":"negative","source":"FDA Orange Book","milestone":"Substance patent 7772243 expires"}],"_dailymed":{"setId":"4ab27d2f-e385-4e9c-b324-fa69c10b855a","title":"VIZIMPRO (DACOMITINIB) TABLET, FILM COATED [PFIZER LABORATORIES DIV PFIZER INC]"},"aiSummary":"Vizimpro (dacomitinib) is an irreversible pan-HER inhibitor approved by the FDA for first-line treatment of metastatic NSCLC harboring EGFR-activating mutations (exon 19 deletion or L858R). As a pan-HER inhibitor, it provides broader kinase coverage than first-generation EGFR TKIs, potentially reducing resistance mechanisms. The drug demonstrates clinical efficacy in both subcutaneous and intracranial tumor models. Dacomitinib targets EGFR/HER1, HER2, and HER4, with additional activity against DDR1, EPHA6, LCK, DDR2, and MNK1 at therapeutic concentrations. Its irreversible binding mechanism and multi-target profile position it as a best-in-class option for EGFR-mutant NSCLC.","ecosystem":[],"mechanism":{"target":"Cyclin-G-associated kinase, Receptor-interacting serine/threonine-protein kinase 2, Receptor-interacting serine/threonine-protein kinase 3","novelty":"best-in-class","targets":[{"gene":"EGFR","source":"DrugCentral","target":"Epidermal growth factor receptor","protein":"Epidermal growth factor receptor"},{"gene":"ERBB2","source":"DrugCentral","target":"Receptor tyrosine-protein kinase erbB-2","protein":"Receptor tyrosine-protein kinase erbB-2"},{"gene":"ERBB4","source":"DrugCentral","target":"Receptor tyrosine-protein kinase erbB-4","protein":"Receptor tyrosine-protein kinase erbB-4"},{"gene":"LCK","source":"DrugCentral","target":"Tyrosine-protein kinase Lck","protein":"Tyrosine-protein kinase Lck"},{"gene":"SRC","source":"DrugCentral","target":"Proto-oncogene tyrosine-protein kinase Src","protein":"Proto-oncogene tyrosine-protein kinase Src"},{"gene":"GAK","source":"DrugCentral","target":"Cyclin-G-associated kinase","protein":"Cyclin-G-associated kinase"},{"gene":"RIPK2","source":"DrugCentral","target":"Receptor-interacting serine/threonine-protein kinase 2","protein":"Receptor-interacting serine/threonine-protein kinase 2"},{"gene":"JAK3","source":"DrugCentral","target":"Tyrosine-protein kinase JAK3","protein":"Tyrosine-protein kinase JAK3"},{"gene":"RIPK3","source":"DrugCentral","target":"Receptor-interacting serine/threonine-protein kinase 3","protein":"Receptor-interacting serine/threonine-protein kinase 3"}],"modality":"small molecule","drugClass":"Tyrosine kinase inhibitor (TKI); Pan-HER inhibitor","explanation":"Dacomitinib is an irreversible inhibitor of the human EGFR family kinases, including EGFR/HER1, HER2, and HER4. It specifically targets tumors driven by EGFR-activating mutations, particularly exon 19 deletions and the exon 21 L858R substitution mutation. The irreversible binding mechanism covalently modifies the ATP-binding pocket, providing sustained kinase inhibition and potentially overcoming resistance mechanisms that develop with reversible inhibitors.\n\nBeyond the HER family, dacomitinib exhibits off-target activity against DDR1, EPHA6, LCK, DDR2, and MNK1 at clinically relevant concentrations. This broader kinase inhibition profile may contribute to its clinical efficacy and potentially reduce the emergence of bypass pathway resistance. The pan-HER approach addresses the limitation of first-generation EGFR TKIs, which are susceptible to HER2-mediated resistance.\n\nPreclinical studies demonstrate dose-dependent inhibition of EGFR and HER2 autophosphorylation with corresponding tumor growth suppression in xenograft models. Notably, dacomitinib shows antitumor activity in intracranial xenografts driven by EGFR amplifications, suggesting adequate CNS penetration—a clinically relevant advantage for patients with brain metastases.","oneSentence":"Irreversible pan-HER kinase inhibitor targeting EGFR, HER2, HER4, and EGFR-activating mutations.","technicalDetail":"Dacomitinib irreversibly inhibits EGFR/HER1, HER2, and HER4 kinase activity through covalent modification of the catalytic domain. It demonstrates potent activity against EGFR exon 19 deletion and L858R mutations while maintaining activity against wild-type EGFR. The drug's pan-HER inhibition and additional off-target kinase activity (DDR1, EPHA6, LCK, DDR2, MNK1) at therapeutic concentrations provide a differentiated pharmacodynamic profile compared to first-generation reversible EGFR TKIs."},"_scrapedAt":"2026-03-27T23:28:21.638Z","_scrapedBy":"cloudflare-swarm","_wikipedia":{"url":"https://en.wikipedia.org/wiki/Dacomitinib","title":"Dacomitinib","extract":"Dacomitinib, sold under the brand name Vizimpro, is a medication for the treatment of non-small-cell lung carcinoma (NSCLC). It is a selective and irreversible inhibitor of EGFR."},"commercial":{"launchDate":"2018","annualCostUS":"$14,400/yr","currentRevenue":"$150M","peakSalesEstimate":"$500M"},"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:37:22.446052+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"name":"Iressa","company":"AstraZeneca","advantage":"First-generation EGFR inhibitor; oral tyrosine kinase inhibitor for EGFR-mutant NSCLC with established safety profile"},{"name":"Tarceva","company":"Roche/Genentech","advantage":"Reversible EGFR inhibitor; widely used for EGFR-mutant lung cancer with extensive clinical data"},{"name":"Tagrisso","company":"AstraZeneca","advantage":"Third-generation EGFR inhibitor; targets T790M resistance mutation and provides improved efficacy over first-generation inhibitors"},{"name":"Gilotrif","company":"Boehringer Ingelheim","advantage":"Second-generation irreversible EGFR inhibitor; similar mechanism to Dacomitinib with comparable efficacy profile"},{"name":"Exkivity","company":"Menarini Group","advantage":"Third-generation EGFR inhibitor; targets exon 20 insertion mutations, addressing a different EGFR mutation subset"}],"indications":{"approved":[{"name":"EGFR mutation-positive, unresectable or recurrent non-small cell lung cancer","diseaseId":"egfr-mutation-positive-unresectable-or-recurrent-non-small-cell-lung-cancer","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Non-small cell lung cancer, positive for epidermal growth factor receptor expression","diseaseId":"non-small-cell-lung-cancer-positive-for-epidermal-growth-factor-receptor-expression","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"_fixedFields":["patents(3)"],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04721106","phase":"","title":"Korea Post Marketing Surveillance (PMS) Study of Vizimpro","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-03-07","conditions":"Lung Neoplasms","enrollment":188},{"nctId":"NCT03810807","phase":"PHASE1","title":"Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-01-17","conditions":"Metastatic Non-small Cell Lung Cancer","enrollment":22},{"nctId":"NCT07267247","phase":"","title":"Cancer Therapy-Related Cardiac Dysfunction Associated With EGFR-TKIs in Advanced EGFR-mutant Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Taichung Veterans General Hospital","startDate":"2022-06-01","conditions":"Non-Small Cell Lung Cancer (MeSH Term: Carcinoma, Non-Small-Cell Lung), Drug-Related Side Effects and Adverse Reactions (MeSH Term), Egfr Tyrosine Kinase Inhibitor","enrollment":100},{"nctId":"NCT04504071","phase":"PHASE2","title":"Dacomitinib in Lung Cancer With Uncommon EGFR Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2020-12-08","conditions":"Non-small Cell Lung Cancer Metastatic, EGF-R Positive Non-Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT06321510","phase":"","title":"A Study to Learn About Dacomitinib in Patients With Non-small Cell Lung Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-07-01","conditions":"Lung Cancer","enrollment":29},{"nctId":"NCT02039336","phase":"PHASE1, PHASE2","title":"Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC","status":"COMPLETED","sponsor":"The Netherlands Cancer Institute","startDate":"2014-04-02","conditions":"Colorectal Cancer","enrollment":35},{"nctId":"NCT04027647","phase":"PHASE2","title":"Phase 2 Study of Dacomitinib in NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Centre, Singapore","startDate":"2019-09-11","conditions":"NSCLC Stage IIIB, NSCLC Stage IIIC, NSCLC Stage IV","enrollment":118},{"nctId":"NCT04946968","phase":"PHASE2","title":"Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Centre, Singapore","startDate":"2021-08-24","conditions":"Advanced Solid Tumours, Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma","enrollment":24},{"nctId":"NCT04609319","phase":"","title":"Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients - A Multi Center Chart Review","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-06-11","conditions":"Lung Cancer","enrollment":307},{"nctId":"NCT04155541","phase":"","title":"Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-01-24","conditions":"EGFR Mutation-positive Inoperable or Reccrent NSCLC","enrollment":40},{"nctId":"NCT03755102","phase":"EARLY_PHASE1","title":"A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-11-21","conditions":"EGFR Gene Mutation, Lung Cancer, Lung Cancer Metastatic","enrollment":17},{"nctId":"NCT05834348","phase":"","title":"A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-06-23","conditions":"Non-Small Cell Lung Cancer","enrollment":5279},{"nctId":"NCT04423185","phase":"PHASE2","title":"PLATFORM Study of Precision Medicine for Rare Tumors","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2020-08-15","conditions":"Rare Tumor","enrollment":770},{"nctId":"NCT06075615","phase":"","title":"A Study to Learn About Dacomitnib in Patients With Non-small Cell Lung Cancer Which Has Spread to the Brain.","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2024-09-30","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":""},{"nctId":"NCT06486142","phase":"PHASE3","title":"EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study","status":"RECRUITING","sponsor":"Region Skane","startDate":"2022-09-21","conditions":"Non-Small Cell Lung Cancer","enrollment":200},{"nctId":"NCT00728390","phase":"PHASE1","title":"A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-12-15","conditions":"Carcinoma, Non-Small Cell, Neoplasm Metastasis","enrollment":74},{"nctId":"NCT04511533","phase":"PHASE4","title":"Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-08-27","conditions":"Metastatic Non Small Cell Lung Cancer","enrollment":101},{"nctId":"NCT03878524","phase":"PHASE1","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-04-01","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia","enrollment":2},{"nctId":"NCT02925234","phase":"PHASE2","title":"The Drug Rediscovery Protocol (DRUP Trial)","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2016-08","conditions":"Cancer, Tumors, Neoplasm","enrollment":1550},{"nctId":"NCT04397432","phase":"","title":"Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Retrospective Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tian Xie","startDate":"2020-08-28","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":878},{"nctId":"NCT01774721","phase":"PHASE3","title":"ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-05-09","conditions":"Non-small Cell Lung Cancer With EGFR-Activating Mutations","enrollment":452},{"nctId":"NCT01000025","phase":"PHASE3","title":"PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2009-12-23","conditions":"Lung Cancer","enrollment":720},{"nctId":"NCT05271916","phase":"PHASE1, PHASE2","title":"First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations","status":"RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2022-10-13","conditions":"Non-Small Cell Lung Cancer (NSCLC)","enrollment":140},{"nctId":"NCT04811001","phase":"PHASE2","title":"Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations","status":"UNKNOWN","sponsor":"Fondazione Ricerca Traslazionale","startDate":"2020-06-12","conditions":"NSCLC","enrollment":170},{"nctId":"NCT01920061","phase":"PHASE1","title":"A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-09-10","conditions":"Neoplasm","enrollment":110},{"nctId":"NCT01520870","phase":"PHASE2","title":"Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.","status":"COMPLETED","sponsor":"Grupo Español de Investigación en Neurooncología","startDate":"2012-02","conditions":"Glioblastoma, Brain Tumor, Recurrent","enrollment":49},{"nctId":"NCT01728233","phase":"PHASE2","title":"Dacomitinib (PF-00299804) in Advanced/Metastatic Squamous Cell Carcinoma of the Penis","status":"COMPLETED","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2013-06-15","conditions":"Penile Neoplasms, Carcinoma, Squamous Cell","enrollment":32},{"nctId":"NCT04768491","phase":"","title":"Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC","status":"UNKNOWN","sponsor":"Peking Union Medical College","startDate":"2020-09-01","conditions":"EGFR Activating Mutation, NSCLC Stage IV, NSCLC Stage IIIB","enrollment":82},{"nctId":"NCT00768664","phase":"PHASE2","title":"Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-11-04","conditions":"Head and Neck Neoplasms","enrollment":69},{"nctId":"NCT04675008","phase":"PHASE2","title":"Central Nervous System(CNS) Efficacy of Dacomitinib","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2020-12-07","conditions":"Non Small Cell Lung Cancer, Brain Metastases","enrollment":30},{"nctId":"NCT03865446","phase":"PHASE1","title":"Evaluate Severe Hepatic Impairment on Dacomitinib PK","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-04-05","conditions":"Severe Hepatic Impairment","enrollment":16},{"nctId":"NCT04575415","phase":"","title":"Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study","status":"UNKNOWN","sponsor":"Guangdong Association of Clinical Trials","startDate":"2020-10-07","conditions":"NSCLC","enrollment":272},{"nctId":"NCT00553254","phase":"PHASE2","title":"Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-02-05","conditions":"Carcinoma, Non Small Cell Lung","enrollment":55},{"nctId":"NCT02382796","phase":"PHASE2","title":"A Rollover Protocol of Dacomitinib For Patients In Japan","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-07-10","conditions":"NSCLC","enrollment":7},{"nctId":"NCT04339829","phase":"PHASE2","title":"An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases","status":"UNKNOWN","sponsor":"Guangdong Association of Clinical Trials","startDate":"2020-08-01","conditions":"Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases","enrollment":50},{"nctId":"NCT01918761","phase":"PHASE1","title":"Dacomitinib + Pemetrexed for Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)","status":"TERMINATED","sponsor":"Central European Cooperative Oncology Group","startDate":"2013-07-30","conditions":"Non Small Cell Lung Cancer","enrollment":5},{"nctId":"NCT01441128","phase":"PHASE1","title":"-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-09-01","conditions":"Carcinoma, Non-Small Cell Lung, Adenocarcinoma, Carcinoma, Squamous Cell","enrollment":20},{"nctId":"NCT00548093","phase":"PHASE2","title":"PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-04-29","conditions":"Carcinoma, Non Small Cell Lung","enrollment":66},{"nctId":"NCT01465802","phase":"PHASE2","title":"Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-12-26","conditions":"Non Small Cell Lung Cancer (NSCLC)","enrollment":236},{"nctId":"NCT00818441","phase":"PHASE2","title":"Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-03-11","conditions":"Carcinoma, Non-small Cell","enrollment":119},{"nctId":"NCT00225121","phase":"PHASE1","title":"Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-00299804 In Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Pfizer","startDate":"2005-10-11","conditions":"Neoplasms","enrollment":121},{"nctId":"NCT01112527","phase":"PHASE2","title":"PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2010-04","conditions":"Glioblastoma, GBM, Glioblastoma Multiforme","enrollment":58},{"nctId":"NCT00728468","phase":"PHASE1","title":"A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-09","conditions":"Advanced Malignant Solid Tumors","enrollment":16},{"nctId":"NCT01858389","phase":"PHASE2","title":"A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-07","conditions":"Non-small Cell Lung Cancer","enrollment":41},{"nctId":"NCT01360554","phase":"PHASE3","title":"ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-06-16","conditions":"Non-Small Cell Lung Cancer","enrollment":878},{"nctId":"NCT02047747","phase":"PHASE2","title":"A Phase II Study of Dacomitinib in Progressive Brain Metastases","status":"TERMINATED","sponsor":"David Piccioni, M.D., Ph.D","startDate":"2014-02","conditions":"Brain Cancer","enrollment":4},{"nctId":"NCT01608022","phase":"PHASE2","title":"A Phase II Trial of PF-00299804 in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2012-07","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":48},{"nctId":"NCT02268747","phase":"PHASE2","title":"Efficacy and Safety of Dacomitinib in the Treatment of Skin Squamous Cell Cancer","status":"UNKNOWN","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2014-11","conditions":"Skin Squamous Cell Cancer","enrollment":43},{"nctId":"NCT01737008","phase":"PHASE1","title":"Dacomitinib Plus Radiotherapy, With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2013-01","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":12},{"nctId":"NCT01152853","phase":"PHASE2","title":"PF-00299804 Monotherapy in Patients With HER-2 Positive Advance Gastric Cancer","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2010-07","conditions":"Advanced Gastric Cancer, HER2","enrollment":28},{"nctId":"NCT01121575","phase":"PHASE1","title":"A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-08","conditions":"Non Small Cell Lung Cancer","enrollment":70},{"nctId":"NCT01796327","phase":"PHASE1","title":"A Study To Assess Absorption Of Study Drug Dacomitinib (PF-00299804), Given As An Oral Tablet Compared To An Intravenous Infusion In Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-04","conditions":"Healthy Volunteers","enrollment":14},{"nctId":"NCT00769067","phase":"PHASE2","title":"A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-11","conditions":"Non-small Cell Lung Cancer","enrollment":188},{"nctId":"NCT01484847","phase":"NA","title":"A Study of PF-00299804 When Given Through a Feeding Tube in Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2011-12","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":6},{"nctId":"NCT01116843","phase":"PHASE1, PHASE2","title":"Study to Assess Biomarkers in Patients With Resectable Oral Cavity Cancer Randomized to Receive Preoperative Treatment","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2010-05","conditions":"Oral Cavity Cancer","enrollment":13},{"nctId":"NCT02097433","phase":"PHASE1","title":"Dacomitinib (PF-00299804) Pharmacokinetics In Chinese Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-07","conditions":"Healthy","enrollment":14},{"nctId":"NCT01449201","phase":"PHASE2","title":"PF-00299804 in Patients With Head and Neck Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2011-10","conditions":"Head Neck Cancer Squamous Cell Metastatic, Head Neck Cancer Squamous Cell Recurrent","enrollment":49},{"nctId":"NCT01702506","phase":"PHASE1","title":"Evaluation Of The Potential Effect That The Administration Of Food Or Antacid Medication May Have In The Oral Absorption Of Dacomitinib (PF-00299804)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-10","conditions":"Healthy Volunteers","enrollment":24},{"nctId":"NCT01571388","phase":"PHASE1","title":"A Study To Compare Pharmacokinetics Of Dacomitinib (PF-00299804) Between Healthy Subjects And Subjects With Mild And Moderate Hepatic Impairment","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-04","conditions":"Healthy, Otherwise Healthy Volunteers With Mild or Moderate Hepatic Dysfunction","enrollment":25},{"nctId":"NCT01318031","phase":"PHASE1","title":"Study To Investigate The Potential Drug Drug Interaction (DDI) Between PF-00299804 And Paroxetine In Healthy Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-03","conditions":"Healthy Volunteers","enrollment":14},{"nctId":"NCT00971191","phase":"PHASE1","title":"A Study In Patients Who Will Undergo Surgical Removal Of Non-Small Cell Lung Cancer To Evaluate Molecular Changes That Occur In Tumor Tissue After Short Term Exposure To PF-00299804","status":"TERMINATED","sponsor":"Pfizer","startDate":"2010-02","conditions":"Non-Small Cell Lung Cancer (NSCLC)","enrollment":22},{"nctId":"NCT01313793","phase":"PHASE1","title":"A Bioequivalence (BE) Study Comparing The Commericializable And Clinical Formulations Of PF-00299804","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-04","conditions":"Healthy Volunteers","enrollment":32},{"nctId":"NCT00783328","phase":"PHASE1","title":"A Study Of PF-00299804 In Patients In Japan With Advanced Malignant Solid Tumors","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-11","conditions":"Neoplasms","enrollment":13},{"nctId":"NCT01034748","phase":"PHASE1","title":"A Radiolabeled Mass Balance Study Of [14C]PF-00299804 In Healthy Male Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-01","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":6},{"nctId":"NCT00999817","phase":"PHASE1","title":"A Pharmacokinetic (PK) Study Of PF-00299804 And Dextromethorphan In Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-11","conditions":"Healthy Volunteers","enrollment":14}],"_emaApprovals":[{"name":"Vizimpro","status":"Authorised","regulator":"EMA"}],"_faersSignals":[{"count":95,"reaction":"DEATH"},{"count":37,"reaction":"DIARRHOEA"},{"count":34,"reaction":"NEOPLASM PROGRESSION"},{"count":26,"reaction":"RASH"},{"count":13,"reaction":"PARONYCHIA"},{"count":9,"reaction":"DECREASED APPETITE"},{"count":8,"reaction":"PAIN"},{"count":7,"reaction":"VOMITING"},{"count":6,"reaction":"DYSPNOEA"},{"count":6,"reaction":"OFF LABEL USE"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral"},"_patentsChecked":true,"crossReferences":{"unii":"5092U85G58","rxcui":"2058849","splId":"cf672c83-c9d9-4107-bcf1-76d4106537cc","chemblId":"CHEMBL2105719","pubchemSID":"87350563"},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[{"period":"2018-","companyName":"Pfizer","relationship":"Original Developer"},{"period":"present","companyName":"Pfizer","relationship":"Current Owner"},{"period":"2019","companyName":"Pfizer Europe Ma Eeig","relationship":"EMA Licensee"},{"period":"2019","companyName":"Pfizer Japan Inc.","relationship":"PMDA Licensee"}],"publicationCount":421,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"approved","brandName":"Vizimpro","genericName":"Dacomitinib","companyName":"Pfizer Inc.","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"2018","enrichmentLevel":4,"visitCount":8,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2018-09-27T00:00:00.000Z","mah":"PFIZER","brand_name_local":null,"application_number":"NDA211288"},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"14400.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":18,"withResults":6},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:37:22.446052+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}